FRANCES RIDENOUR: Open Payments
NPI 1528518339 · LONGVIEW, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$731 in 19 payments from 12 companies in 2025. Trend: 2023 $416 · 2024 $786 · 2025 $731
Food & beverage: $731
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 2 | $135 |
| Corcept Therapeutics | 1 | $125 |
| Novo Nordisk Inc | 1 | $125 |
| AstraZeneca Pharmaceuticals LP | 5 | $120 |
| Sumitomo Pharma America, Inc. | 1 | $71 |
| GlaxoSmithKline, LLC. | 2 | $43 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $40 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
| Edwards Lifesciences Corporation | 1 | $14 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $14 |
Products named: Korlym, KISUNLA, GEMTESA, FARXIGA, BREZTRI, TRELEGY ELLIPTA, CAPLYTA, RELISTOR.
Industry payments across TX — which companies pay providers there.
